ECSP20080272A - DERIVADOS DE TIOFENO PARA EL TRATAMIENTO DE TRASTORNOS CAUSADOS POR IgE - Google Patents

DERIVADOS DE TIOFENO PARA EL TRATAMIENTO DE TRASTORNOS CAUSADOS POR IgE

Info

Publication number
ECSP20080272A
ECSP20080272A ECSENADI202080272A ECDI202080272A ECSP20080272A EC SP20080272 A ECSP20080272 A EC SP20080272A EC SENADI202080272 A ECSENADI202080272 A EC SENADI202080272A EC DI202080272 A ECDI202080272 A EC DI202080272A EC SP20080272 A ECSP20080272 A EC SP20080272A
Authority
EC
Ecuador
Prior art keywords
ige
treatment
disorders caused
thiophene derivatives
thiophene
Prior art date
Application number
ECSENADI202080272A
Other languages
English (en)
Inventor
Rickki Lee Connelly
Gregory William Haslett
Matthew Duncan Selby
Suganthan Selvaratnam
Judi Charlotte Neuss
Alistair James Henry
Timothy John Norman
Oliver Philps
Zhaoning Zhu
Giancarl Trani
William Ross Pitt
James Madden
Richard Jeremy Franklin
Prafulkumar Tulshibhai Chovatia
Konstantinos Rampalakos
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of ECSP20080272A publication Critical patent/ECSP20080272A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan derivados de tiofeno de fórmula (I) y una de sus sales farmacéuticamente aceptables. Estos compuestos tienen utilidad para el tratamiento o prevención de trastornos causados por IgE, tales como alergia, hipersensibilidad tipo 1 o inflamación sinusal familiar.
ECSENADI202080272A 2018-06-21 2020-12-11 DERIVADOS DE TIOFENO PARA EL TRATAMIENTO DE TRASTORNOS CAUSADOS POR IgE ECSP20080272A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18179126 2018-06-21

Publications (1)

Publication Number Publication Date
ECSP20080272A true ECSP20080272A (es) 2021-01-29

Family

ID=62748855

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202080272A ECSP20080272A (es) 2018-06-21 2020-12-11 DERIVADOS DE TIOFENO PARA EL TRATAMIENTO DE TRASTORNOS CAUSADOS POR IgE

Country Status (22)

Country Link
US (1) US12018021B2 (es)
EP (1) EP3810606A1 (es)
JP (1) JP7657056B2 (es)
KR (1) KR102850569B1 (es)
CN (1) CN112566910B (es)
AR (1) AR114973A1 (es)
AU (1) AU2019291111B9 (es)
BR (1) BR112020025510A2 (es)
CA (1) CA3103052A1 (es)
CL (1) CL2020003191A1 (es)
EA (1) EA202190011A1 (es)
EC (1) ECSP20080272A (es)
IL (1) IL279482B2 (es)
MA (1) MA52941A (es)
MX (1) MX2020013882A (es)
PE (1) PE20211803A1 (es)
PH (1) PH12020552162A1 (es)
PY (1) PY1949665A (es)
SG (1) SG11202012308TA (es)
TW (1) TW202016107A (es)
UY (1) UY38271A (es)
WO (1) WO2019243550A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210582A1 (en) * 2019-04-11 2020-10-15 University Of The Sciences Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor
US12365696B2 (en) 2019-05-10 2025-07-22 Dana-Farber Cancer Institute, Inc. Small-molecule focal adhesion kinase (FAK) inhibitors
GB201919214D0 (en) 2019-12-23 2020-02-05 Ucb Biopharma Sprl Tetrahydrobenzo-quinoline sulfonamide derivatives useful as IGE modulators
GB201919212D0 (en) 2019-12-23 2020-02-05 Ucb Biopharma Sprl Dihydro-cyclopenta-isoquinoline sulfonamides derivatives
GB201919213D0 (en) 2019-12-23 2020-02-05 Ucb Biopharma Sprl Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds
CN116531369A (zh) * 2023-02-24 2023-08-04 杜娟娟 一种化合物在促进伤口愈合药物中的应用
JP2026511124A (ja) * 2023-03-21 2026-04-10 ニューラシック セラピューティクス インコーポレイテッド 置換チオフェン縮合シクロヘキサノン誘導体、それを含む組成物及び医薬品としてのそれらの使用
IL325120A (en) * 2023-06-05 2026-02-01 Celloram Inc Fatty acid binding protein (FABP) inhibitors, methods of use and methods of preparation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU616916B2 (en) * 1987-11-20 1991-11-14 Kissei Pharmaceutical Co. Ltd. 4h-quinolizin-4-one compounds exhibiting therapeutic activities
WO2001017516A2 (en) * 1999-09-10 2001-03-15 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
JP4548882B2 (ja) * 1999-11-30 2010-09-22 興和創薬株式会社 ４，５，６，７−テトラヒドロチエノ〔２，３−ｃ〕ピリジン化合物
JP2001151789A (ja) * 1999-11-30 2001-06-05 Kao Corp アルキルグリコシドの製造方法
AU2207001A (en) * 1999-12-24 2001-07-09 Smithkline Beecham Plc Novel compounds and process
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
US20040171603A1 (en) 2001-05-18 2004-09-02 Janos Pato Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor
EP1670804A2 (en) * 2003-09-10 2006-06-21 GPC Biotech AG Heterobicyclic compounds as pharmaceutically active agents
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
WO2006122546A1 (de) 2005-05-18 2006-11-23 Forschungsverbund Berlin E.V. Nicht-peptidische inhibitoren der akap-pka-wechselwirkung
US8338623B2 (en) * 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US20110015239A1 (en) * 2007-12-14 2011-01-20 The Regents Of The University Of California Inhibitors of calcium-activated chloride channels
AU2014304562B8 (en) 2013-08-08 2018-07-05 Galapagos Nv Thieno[2,3-c]pyrans as CFTR modulators

Also Published As

Publication number Publication date
PY1949665A (es) 2019-12-26
MX2020013882A (es) 2021-05-27
IL279482A (en) 2021-01-31
IL279482B1 (en) 2024-07-01
TW202016107A (zh) 2020-05-01
PH12020552162A1 (en) 2021-06-28
KR102850569B1 (ko) 2025-08-26
EP3810606A1 (en) 2021-04-28
WO2019243550A1 (en) 2019-12-26
AU2019291111A1 (en) 2021-01-21
EA202190011A1 (ru) 2021-04-27
KR20210024571A (ko) 2021-03-05
CN112566910B (zh) 2025-09-09
CL2020003191A1 (es) 2021-07-02
JP2021527665A (ja) 2021-10-14
UY38271A (es) 2020-01-31
AU2019291111B2 (en) 2023-07-06
US12018021B2 (en) 2024-06-25
JP7657056B2 (ja) 2025-04-04
US20220332709A1 (en) 2022-10-20
MA52941A (fr) 2021-04-28
CA3103052A1 (en) 2019-12-26
BR112020025510A2 (pt) 2021-03-09
CN112566910A (zh) 2021-03-26
AR114973A1 (es) 2020-11-11
SG11202012308TA (en) 2021-01-28
IL279482B2 (en) 2024-11-01
AU2019291111B9 (en) 2023-08-24
PE20211803A1 (es) 2021-09-14

Similar Documents

Publication Publication Date Title
UY38271A (es) Derivados de tiofeno para el tratamiento de trastornos causados por ige
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
SA518391624B1 (ar) Ror- منظمات جاما
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
UY40873A (es) Compuestos cíclicos puenteados y composiciones farmacéuticas y usos de los mismos para modular la respuesta integrada al estrés y para tratar enfermedades relacionadas
CR20160456A (es) Compuestos de heteroarilo o arilo bibíclicos fusionados
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
GT201700107A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
CO7160077A2 (es) Compuestos de pirazol sustituidos como antagonistas de lpar
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.